BIOMAT Database Logo BIOMAT Database Logo

Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. 2003

Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA. shlai@jhsph.edu

Recent evidence suggests that as a group protease inhibitors (PIs) may accelerate certain factors associated with atherosclerosis. The objective of this study was to evaluate the effect of individual PIs (indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) on certain factors associated with atherosclerosis. Persons who took saquinavir and/or ritonavir were compared with those on other PIs. Between May 2000 and July 2001, the lipid profiles, C-reactive protein (CRP) levels, coronary artery calcium (CAC) scores, and blood cell morphologic parameters were measured in 98 black adult participants aged 25 to 45 years with HIV-1 infection in Baltimore, Maryland. Among these 98, there were 55 (56.1%) taking PIs. Students' t-test and chi2 test were used to detect the between-group differences. Study participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, red and white blood cell counts, time since HIV diagnosis, and duration on anti-retroviral therapy. Compared with those who took non-PI regimens, those who took indinavir, nelfinavir, or saquinavir had significantly higher levels of mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH). Those taking any PI had significantly higher total cholesterol and low-density lipoprotein. Those taking nelfinavir, ritonavir, or saquinavir were more likely to have a higher CAC score (>5) than those on non-PI regimens. There were no differences in the lipid profiles, MCV, MCH, CRP, and CAC between those taking saquinavir and/or ritonavir and those taking other PIs. Overall, the changes noted might lead to anticipation of clinical changes linked to accelerated atherosclerosis in patients on PIs.

UI MeSH Term Description Entries
D008297 Male Males
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses

Related Publications

Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors.
November 1997, AIDS (London, England),
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Hyperglycemia associated with protease inhibitors in HIV-1-infected patients.
July 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Lipid and glucose metabolism in HIV-1-infected children treated with protease inhibitors.
January 2002, Archives of disease in childhood,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
August 2001, AIDS research and human retroviruses,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
[Diabetes mellitus associated with protease inhibitors in HIV infected patients].
September 1998, La Revue de medecine interne,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
January 2003, HIV medicine,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.
November 2000, AIDS (London, England),
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Prevalence and factors associated with sleep disturbances among early-treated HIV-infected persons.
May 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
HIV protease inhibitors and atherosclerosis.
February 2003, The Journal of clinical investigation,
Shenghan Lai, and Hong Lai, and David D Celentano, and David Vlahov, and Shiquan Ren, and Joseph Margolick, and Joao A C Lima, and John G Bartlett
Factors associated with fractures in HIV-infected persons: which factors matter?
January 2017, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
Copied contents to your clipboard!